Here are the S-3 shelf registrations from Niki BioSolutions, Inc. (NIKI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow NIKI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NIKI filings page.
Niki BioSolutions, Inc. (NIKI) filed a pre-effective amendment to a shelf registration for offerings with an aggregate offering price of up to $75,000,000. The securities may include common or preferred stock, warrants, subscription rights, debt securities, units, or combinations. Sales may occur only after the registration statement becomes effective, with specific terms provided in a prospectus supplement.
The amendment adds Hong Kong legal and operational risk disclosure in response to SEC comments. Niki says its principal business operations are in Hong Kong and describes possible effects of PRC regulatory developments on operations and future offerings. Separately, DiamiR, Niki’s wholly owned subsidiary, received a going-concern warning in its auditor’s report for the year ended May 31, 2026; management believes its capital is insufficient to fund operations for the next 12 months.
Niki BioSolutions, Inc. (NIKI) filed a pre-effective amendment to its shelf registration statement to offer, from time to time after effectiveness, up to $75,000,000 of common stock, preferred stock, warrants, subscription rights, debt securities and units. The company qualifies as a smaller reporting company and is using the Nasdaq Capital Market listing of its common stock under the symbol NIKI as the primary trading venue.
The prospectus emphasizes that Niki is a Delaware holding company whose principal operations are conducted through subsidiaries, with a significant portion of its business in Hong Kong. It highlights extensive legal and operational risks related to PRC and Hong Kong regulation, including potential intervention by Chinese authorities, evolving cybersecurity and data rules, and the Holding Foreign Companies Accountable Act, any of which could materially affect operations or render the common stock significantly less valuable or worthless.
The document also discloses that Niki’s key subsidiary DiamiR is a pre-commercial clinical-stage business that has incurred losses, has no product sales and whose auditors raised substantial doubt about its ability to continue as a going concern, meaning the group expects to require significant additional capital. The company details internal cash-transfer practices among entities, notes substantial historical funding of various subsidiaries, and states that as of the prospectus date it has obtained all permissions necessary to operate, though future regulatory changes could constrain capital flows, business activities or access to U.S. capital markets.
Niki BioSolutions, Inc. (NIKI) has filed a Form S-3 shelf registration (as amended by Pre-Effective Amendment No. 1) to offer, from time to time, an aggregate of up to $75,000,000 of common stock, preferred stock, warrants, subscription rights, debt securities and units. This new S-3 replaces a prior Form F-3 shelf, as the company is no longer a foreign private issuer and no securities were sold under that earlier filing.
Niki BioSolutions is a clinical-stage life sciences company focused on genomic and biomarker testing through a CLIA-certified, CAP-accredited lab, with its common stock listed on Nasdaq under the symbol NIKI. As of August 25, 2026, public float was $20.4 million, and the company qualifies as a smaller reporting company, limiting primary offerings to no more than one-third of that float in any 12‑month period while the float remains below $75 million. The company has experienced recent net losses, and its and DiamiR Biosciences Corp.’s audited financial statements carry going concern explanatory paragraphs from their auditors.
Unless specified otherwise in a prospectus supplement, net proceeds from any future takedowns under this shelf will be used for general corporate purposes, including working capital and potentially repayment of outstanding debt. The filing also describes the capital structure, including common stock, non‑voting non‑convertible Series A preferred stock with a 70/30 liquidation allocation, existing warrants, and standard Delaware anti‑takeover and indemnification provisions.